Proteintech, 15421-1-AP-20ul, ACLY Polyclonal antibody

15421-1-AP targets ACLY in WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Applications
Positive WB detected in: A549 cells, HeLa cells, L02 cells, Jurkat cells, mouse brain tissue, rat brain tissue, K-562 cells, MCF-7 cells, mouse liver tissue, rat liver tissue
Positive IP detected in: HeLa cells
Positive IHC detected in: human prostate cancer tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive IF/ICC detected in: A549 cells
Positive FC (Intra) detected in: HepG2 cells
Recommended dilution
Western Blot (WB): WB : 1:5000-1:50000
Immunoprecipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC): IHC : 1:50-1:500
Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500
Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension
Background Information
ACLY(ATP-citrate synthase) is also named as ACL. It is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA. ACLY serves as not only a target in oxygenated cells for suppression of lipid synthesis and histone acetylation, but also as a susceptible target in hypoxic cells to restore inhibition of glycolysis. In nonsmall cell lung carcinoma and hepatocellular carcinoma, ACLY is overexpressed compared with normal parenchyma suggesting that ACLY may represent a common target among highly malignant tumors(PMID:19795461). This protein has 2 isoforms produced by alternative splicing.